| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.01 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.17 | 0.02 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.02 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.02 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.03 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.092 | 0.03 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.091 | 0.03 |